Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma

The biology and clinical impact of bone marrow (BM) infiltration in patients with diffuse large B-cell lymphoma (DLBCL) remains unclear in the rituximab era. We retrospectively analyzed 232 patients diagnosed with DLBCL at our center between 1999 and 2014. Concordant-presence of large cells similar...

Full description

Bibliographic Details
Main Authors: Sara Alonso-Álvarez, Miguel Alcoceba, María García-Álvarez, Oscar Blanco, Marta Rodríguez, Mónica Baile, Juan Carlos Caballero, Julio Dávila, María Belén Vidriales, Carmen Esteban, Piedad Arias, Luis G. Díaz, Pilar Tamayo, María Dolores Caballero, Norma C. Gutiérrez, Marcos González, Alejandro Martín
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/2/474
id doaj-27e328c0914244d3be40dac9bd3f7679
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Sara Alonso-Álvarez
Miguel Alcoceba
María García-Álvarez
Oscar Blanco
Marta Rodríguez
Mónica Baile
Juan Carlos Caballero
Julio Dávila
María Belén Vidriales
Carmen Esteban
Piedad Arias
Luis G. Díaz
Pilar Tamayo
María Dolores Caballero
Norma C. Gutiérrez
Marcos González
Alejandro Martín
spellingShingle Sara Alonso-Álvarez
Miguel Alcoceba
María García-Álvarez
Oscar Blanco
Marta Rodríguez
Mónica Baile
Juan Carlos Caballero
Julio Dávila
María Belén Vidriales
Carmen Esteban
Piedad Arias
Luis G. Díaz
Pilar Tamayo
María Dolores Caballero
Norma C. Gutiérrez
Marcos González
Alejandro Martín
Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma
Cancers
bone marrow involvement
diffuse large b-cell lymphoma
discordant bone marrow
concordant bone marrow
cns relapse
author_facet Sara Alonso-Álvarez
Miguel Alcoceba
María García-Álvarez
Oscar Blanco
Marta Rodríguez
Mónica Baile
Juan Carlos Caballero
Julio Dávila
María Belén Vidriales
Carmen Esteban
Piedad Arias
Luis G. Díaz
Pilar Tamayo
María Dolores Caballero
Norma C. Gutiérrez
Marcos González
Alejandro Martín
author_sort Sara Alonso-Álvarez
title Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma
title_short Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma
title_full Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma
title_fullStr Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma
title_full_unstemmed Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma
title_sort biological features and prognostic impact of bone marrow infiltration in patients with diffuse large b-cell lymphoma
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2020-02-01
description The biology and clinical impact of bone marrow (BM) infiltration in patients with diffuse large B-cell lymphoma (DLBCL) remains unclear in the rituximab era. We retrospectively analyzed 232 patients diagnosed with DLBCL at our center between 1999 and 2014. Concordant-presence of large cells similar to those of the lymph node biopsy- and discordant-infiltration by small cells forming lymphoid aggregates, lacking cytological atypia-BM infiltration was defined by histological criteria and further characterized by flow cytometry (FCM). Cell of origin (COO) was determined using Hans&#8217; algorithm. For the clonal relationship between tumor and discordant BM, the VDJH rearrangement was analyzed. Survival analyses were restricted to 189 patients treated with rituximab and chemotherapy. Thirty-six (16%) had concordant, and 37 (16%) discordant BM infiltration. FCM described different indolent lymphomas among discordant cases, clonally related with DLBCL in 10/13 available samples. Median follow-up was 58 months. 5-year-progression-free survival (PFS) for non-infiltrated, discordant and concordant groups was 68%, 65% and 30%, respectively (<i>p</i> &lt; 0.001). Combining COO and BM infiltration, patients with discordant BM and non-germinal center B-cell COO also had decreased 5-year-PFS (41.9%). In multivariate analysis, concordant BM had an independent effect on PFS (HR 2.5, <i>p</i> = 0.01). Five-year cumulative incidence of central nervous system (CNS) relapse was 21%, 4% and 1% in concordant, discordant and non-infiltrated groups, respectively (<i>p</i> &lt; 0.001). In conclusion, concordant BM infiltration represents a subset with poor prognosis, whereas the prognostic impact of discordant BM infiltration could be limited to non-CGB cases.
topic bone marrow involvement
diffuse large b-cell lymphoma
discordant bone marrow
concordant bone marrow
cns relapse
url https://www.mdpi.com/2072-6694/12/2/474
work_keys_str_mv AT saraalonsoalvarez biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT miguelalcoceba biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT mariagarciaalvarez biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT oscarblanco biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT martarodriguez biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT monicabaile biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT juancarloscaballero biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT juliodavila biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT mariabelenvidriales biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT carmenesteban biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT piedadarias biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT luisgdiaz biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT pilartamayo biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT mariadolorescaballero biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT normacgutierrez biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT marcosgonzalez biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
AT alejandromartin biologicalfeaturesandprognosticimpactofbonemarrowinfiltrationinpatientswithdiffuselargebcelllymphoma
_version_ 1724801583336652800
spelling doaj-27e328c0914244d3be40dac9bd3f76792020-11-25T02:36:04ZengMDPI AGCancers2072-66942020-02-0112247410.3390/cancers12020474cancers12020474Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell LymphomaSara Alonso-Álvarez0Miguel Alcoceba1María García-Álvarez2Oscar Blanco3Marta Rodríguez4Mónica Baile5Juan Carlos Caballero6Julio Dávila7María Belén Vidriales8Carmen Esteban9Piedad Arias10Luis G. Díaz11Pilar Tamayo12María Dolores Caballero13Norma C. Gutiérrez14Marcos González15Alejandro Martín16Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Pathology, University Hospital of Salamanca (HUS/IBSAL), 37007 Salamanca, SpainDepartment of Pathology, University Hospital of Salamanca (HUS/IBSAL), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of General and Gastrointestinal Surgery, University Hospital of Salamanca (HUS/IBSAL), 37007 Salamanca, SpainDepartment of Radiology, University Hospital of Salamanca (HUS/IBSAL), 37007 Salamanca, SpainDepartment of Nuclear Medicine, University Hospital of Salamanca (HUS/IBSAL), 37007 Salamanca, SpainDepartment of Nuclear Medicine, University Hospital of Salamanca (HUS/IBSAL), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainDepartment of Hematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), 37007 Salamanca, SpainThe biology and clinical impact of bone marrow (BM) infiltration in patients with diffuse large B-cell lymphoma (DLBCL) remains unclear in the rituximab era. We retrospectively analyzed 232 patients diagnosed with DLBCL at our center between 1999 and 2014. Concordant-presence of large cells similar to those of the lymph node biopsy- and discordant-infiltration by small cells forming lymphoid aggregates, lacking cytological atypia-BM infiltration was defined by histological criteria and further characterized by flow cytometry (FCM). Cell of origin (COO) was determined using Hans&#8217; algorithm. For the clonal relationship between tumor and discordant BM, the VDJH rearrangement was analyzed. Survival analyses were restricted to 189 patients treated with rituximab and chemotherapy. Thirty-six (16%) had concordant, and 37 (16%) discordant BM infiltration. FCM described different indolent lymphomas among discordant cases, clonally related with DLBCL in 10/13 available samples. Median follow-up was 58 months. 5-year-progression-free survival (PFS) for non-infiltrated, discordant and concordant groups was 68%, 65% and 30%, respectively (<i>p</i> &lt; 0.001). Combining COO and BM infiltration, patients with discordant BM and non-germinal center B-cell COO also had decreased 5-year-PFS (41.9%). In multivariate analysis, concordant BM had an independent effect on PFS (HR 2.5, <i>p</i> = 0.01). Five-year cumulative incidence of central nervous system (CNS) relapse was 21%, 4% and 1% in concordant, discordant and non-infiltrated groups, respectively (<i>p</i> &lt; 0.001). In conclusion, concordant BM infiltration represents a subset with poor prognosis, whereas the prognostic impact of discordant BM infiltration could be limited to non-CGB cases.https://www.mdpi.com/2072-6694/12/2/474bone marrow involvementdiffuse large b-cell lymphomadiscordant bone marrowconcordant bone marrowcns relapse